Do You Have the Data to Benefit from a Post-Keytruda Approval Market?
Genomic Testing Is Necessary to Identify the Right Patients for Treatment
In late May, the oncology market was riveted by the FDA’s approval of Keytruda (pembrolizumab) for adult and pediatric patients with any solid tumor with a specific biomarker referred to as microsatellite instability-high (MSI-H) or mismatch-repair deficient (dMMR)1. Following that announcement, Loxo Pharmaceuticals became the media darling of the American Society of Clinical Oncology meeting, after sharing its preliminary results for larotrectinib (LOXO-101), a candidate for cancers with a different biomarker, TRK or NTRK fusions2. But for all the publicity and speculation about pharmaceutical companies expanding their R&D for “tumor-agnostic” drugs, the in vitro diagnostics (IVD) industry could be the real winner.